MX2009012948A - Nuevas indicaciones para la terapia anti-il-1-beta. - Google Patents
Nuevas indicaciones para la terapia anti-il-1-beta.Info
- Publication number
- MX2009012948A MX2009012948A MX2009012948A MX2009012948A MX2009012948A MX 2009012948 A MX2009012948 A MX 2009012948A MX 2009012948 A MX2009012948 A MX 2009012948A MX 2009012948 A MX2009012948 A MX 2009012948A MX 2009012948 A MX2009012948 A MX 2009012948A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- receptor
- rheumatoid arthritis
- antibodies
- disrupting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención se refiere a un uso novedoso de los compuestos que interrumpen al ligando de IL-1ß/receptor de IL-1 (referidos en la presente como "compuestos de IL-1-beta"); tales como los compuestos moleculares que interrumpen la interacción del ligando lL-1ß - receptor de IL-1, los anticuerpos contra IL-1ß o los anticuerpos contra el receptor de IL-1, por ejemplo, las moléculas de enlace de IL-1ß descritas en la presente, por ejemplo, los anticuerpos que se dan a conocer en la presente, por ejemplo, los compuestos de enlace de IL-1ß o los compuestos de enlace de receptores de lL-1, y/o los compuestos de ARN que disminuyen los niveles de proteína de ya sea los ligandos de IL-1ß o bien los receptores de lL-1, en el tratamiento y/o la prevención de síndromes auto-inflamatorios, por ejemplo, síndrome de artritis reumatoide juvenil o de artritis reumatoide de adultos, y a métodos para el tratamiento y/o la prevención de síndromes auto-inflamatorios, por ejemplo, síndrome de artritis reumatoide juvenil o de artritis reumatoide de adultos, en mamíferos, en particular en seres humanos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07109084 | 2007-05-29 | ||
| PCT/EP2008/056520 WO2008145664A1 (en) | 2007-05-29 | 2008-05-28 | New indications for anti- il-i-beta therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009012948A true MX2009012948A (es) | 2009-12-14 |
Family
ID=38626983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009012948A MX2009012948A (es) | 2007-05-29 | 2008-05-28 | Nuevas indicaciones para la terapia anti-il-1-beta. |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US8282922B2 (es) |
| EP (5) | EP2152308A1 (es) |
| JP (7) | JP2010528086A (es) |
| KR (7) | KR20230130763A (es) |
| CN (2) | CN101678104A (es) |
| AU (1) | AU2008257520B2 (es) |
| BR (1) | BRPI0812040A2 (es) |
| CA (7) | CA3156905C (es) |
| MX (1) | MX2009012948A (es) |
| RU (3) | RU2009148597A (es) |
| WO (1) | WO2008145664A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853150B2 (en) | 2010-07-29 | 2014-10-07 | Eleven Biotherapeutics, Inc. | Chimeric IL-1 receptor type I antagonists |
| EP2603525A1 (en) * | 2010-08-13 | 2013-06-19 | F.Hoffmann-La Roche Ag | Antibodies to il-1beta and il-18, for treatment of disease |
| NZ607510A (en) | 2010-09-10 | 2014-10-31 | Apexigen Inc | Anti-il-1 beta antibodies and methods of use |
| CN103059136A (zh) * | 2012-12-24 | 2013-04-24 | 浙江大学 | 抗中华鳖IL-1β多克隆抗体的制备及在检测中的应用 |
| BR112015022587A2 (pt) | 2013-03-13 | 2017-10-24 | Eleven Biotherapeutics Inc | formulações de citocina quimérica para entrega ocular |
| JP6456015B2 (ja) * | 2013-07-19 | 2019-01-23 | 国立大学法人三重大学 | 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物 |
| UY37758A (es) * | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| EP4093430A4 (en) * | 2020-01-21 | 2024-01-24 | Tavotek Biotherapeutics Hong Kong Ltd | AGENTS THAT INTERFERE WITH IL-1 RECEPTOR SIGNALING? |
| WO2024102997A1 (en) | 2022-11-11 | 2024-05-16 | Peterson Jeff R | Gout flare prevention methods using il-1β inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| CA2165919A1 (en) | 1994-12-26 | 1996-06-27 | Koichi Katsuyama | Agents for inhibiting the production of il-1.beta. and the release of tnf. |
| US5643915A (en) * | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
| GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| EP1712239A3 (en) * | 2000-05-12 | 2007-08-22 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| KR100916613B1 (ko) | 2000-11-07 | 2009-09-14 | 노파르티스 아게 | 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체 |
| KR101004224B1 (ko) | 2002-02-01 | 2010-12-27 | 어리어드 파마슈티칼스, 인코포레이티드 | 인 함유 화합물 및 이의 용도 |
| AR039209A1 (es) | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
| RS20050008A (en) | 2002-07-08 | 2007-06-04 | Pliva-Istraživački Institut D.O.O., | New compounds,compositions and methods for treatment of inflammatory diseases and conditions |
| KR20090088973A (ko) * | 2002-10-17 | 2009-08-20 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| NZ540427A (en) | 2002-12-09 | 2008-04-30 | Univ Texas | Methods for selectively inhibiting janus tyrosine kinase 3 (Jak3) |
| US7261882B2 (en) * | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| KR101164541B1 (ko) | 2004-01-12 | 2012-07-10 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 선택적 키나제 저해제 |
| JP4989456B2 (ja) * | 2004-02-26 | 2012-08-01 | ベイラー リサーチ インスティテュート | 関節炎の全身処置のための組成物および方法 |
| WO2005117945A1 (en) * | 2004-06-04 | 2005-12-15 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat autoinflammatory disease |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| CA2590164A1 (en) * | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| SI1899378T1 (sl) * | 2005-06-21 | 2010-02-26 | Xoma Technology Ltd | IL-1Beta vezavna protitelesa in njihovi fragmenti |
| US20100015146A1 (en) | 2005-10-14 | 2010-01-21 | Novo Nordisk A/S | Treating diabetes using inhibitors of il-1 |
| JP2009513645A (ja) * | 2005-10-26 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | ＩＬ−１β化合物の新規使用 |
| EP2094306A2 (en) * | 2006-12-20 | 2009-09-02 | XOMA Technology Ltd. | Treatment of il-1-beta related diseases |
-
2008
- 2008-05-28 CA CA3156905A patent/CA3156905C/en active Active
- 2008-05-28 CA CA3080328A patent/CA3080328C/en active Active
- 2008-05-28 KR KR1020237029637A patent/KR20230130763A/ko active Application Filing
- 2008-05-28 CN CN200880018047A patent/CN101678104A/zh active Pending
- 2008-05-28 WO PCT/EP2008/056520 patent/WO2008145664A1/en active Application Filing
- 2008-05-28 EP EP08760116A patent/EP2152308A1/en not_active Ceased
- 2008-05-28 KR KR1020097026864A patent/KR101591533B1/ko active IP Right Grant
- 2008-05-28 EP EP22196860.5A patent/EP4177268A3/en active Pending
- 2008-05-28 CA CA2947947A patent/CA2947947C/en active Active
- 2008-05-28 EP EP18177247.6A patent/EP3406263A1/en not_active Withdrawn
- 2008-05-28 KR KR1020217011722A patent/KR20210047376A/ko active Application Filing
- 2008-05-28 MX MX2009012948A patent/MX2009012948A/es not_active Application Discontinuation
- 2008-05-28 KR KR1020197005950A patent/KR20190025056A/ko not_active Application Discontinuation
- 2008-05-28 KR KR1020187008103A patent/KR20180032687A/ko not_active Application Discontinuation
- 2008-05-28 CA CA2687499A patent/CA2687499C/en active Active
- 2008-05-28 EP EP12158373A patent/EP2468301A1/en not_active Ceased
- 2008-05-28 CA CA2993565A patent/CA2993565C/en active Active
- 2008-05-28 CA CA3030662A patent/CA3030662C/en active Active
- 2008-05-28 EP EP12158424A patent/EP2468302A1/en not_active Ceased
- 2008-05-28 JP JP2010509810A patent/JP2010528086A/ja active Pending
- 2008-05-28 CN CN201510324201.1A patent/CN104873972A/zh active Pending
- 2008-05-28 KR KR1020227012190A patent/KR102606597B1/ko active IP Right Grant
- 2008-05-28 US US12/601,280 patent/US8282922B2/en active Active
- 2008-05-28 RU RU2009148597/15A patent/RU2009148597A/ru unknown
- 2008-05-28 AU AU2008257520A patent/AU2008257520B2/en active Active
- 2008-05-28 BR BRPI0812040-4A2A patent/BRPI0812040A2/pt not_active Application Discontinuation
- 2008-05-28 CA CA3213888A patent/CA3213888A1/en active Pending
- 2008-05-28 KR KR1020167002268A patent/KR20160017119A/ko not_active Application Discontinuation
-
2012
- 2012-08-17 US US13/587,978 patent/US8524667B2/en active Active
-
2013
- 2013-07-31 US US13/955,673 patent/US9168298B2/en active Active
-
2014
- 2014-01-15 RU RU2014101207A patent/RU2698208C9/ru active
- 2014-07-03 JP JP2014137895A patent/JP6454098B2/ja active Active
-
2015
- 2015-09-22 US US14/861,191 patent/US9534047B2/en active Active
-
2016
- 2016-07-01 JP JP2016131312A patent/JP2016183187A/ja not_active Withdrawn
- 2016-11-23 US US15/359,784 patent/US10106604B2/en not_active Expired - Fee Related
-
2018
- 2018-03-07 JP JP2018040956A patent/JP6685339B2/ja active Active
- 2018-09-13 US US16/129,921 patent/US10968272B2/en active Active
-
2019
- 2019-08-15 RU RU2019125748A patent/RU2019125748A/ru unknown
-
2020
- 2020-03-30 JP JP2020060389A patent/JP7069242B2/ja active Active
-
2021
- 2021-02-26 US US17/186,301 patent/US20210179705A1/en active Pending
-
2022
- 2022-05-02 JP JP2022075912A patent/JP7459166B2/ja active Active
-
2024
- 2024-03-18 JP JP2024042358A patent/JP2024069547A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500559A1 (en) | Novel use of il-1beta compounds | |
| MX2009012948A (es) | Nuevas indicaciones para la terapia anti-il-1-beta. | |
| NL301089I1 (es) | ||
| MX2009006891A (es) | Anticuerpos cd44. | |
| WO2008071418A3 (en) | Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases | |
| PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| MX353319B (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
| UA91815C2 (ru) | Выделенное антитело, которое специфически связывает gdf-8, и его применение | |
| MX2009008608A (es) | Anticuerpos monoclonales anti-cxcl13. | |
| MA32982B1 (fr) | Proteines de liaison au recepteur cgrp humain | |
| WO2005012242A3 (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides | |
| TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
| UA86599C2 (en) | Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides | |
| WO2007068750A3 (en) | Immunoglobulins directed against nogo | |
| EA201170795A1 (ru) | Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола | |
| WO2008108830A8 (en) | Immunogenic and therapeutic compositions for streptococcus pyogenes | |
| DK2044125T3 (da) | Sammensætninger og fremgangsmåder til indgivelse af aktiverede anti-ras-antistoffer i celler | |
| EA200702634A1 (ru) | Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения | |
| WO2005053728A3 (de) | Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik | |
| DK1143994T3 (da) | Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme | |
| WO2006048657A3 (en) | Fras related protein | |
| TH126306B (th) | การใช้งานแบบใหม่ของสารประกอบ il-1 เบตา | |
| TH126306A (th) | การใช้งานแบบใหม่ของสารประกอบ il-1 เบตา | |
| UA87851C2 (ru) | Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом | |
| RS20060322A (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |